The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Blood Component Removal

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Blood Component Removal


High impact information on Blood Component Removal

  • Adverse effects of apheresis included the need for a central venous catheter (9 patients), major vasovagal episodes (3 patients), and severe citrate reactions (2 patients) [6].
  • Ethylene oxide gas, which was used to sterilize plastic components in the disposable apheresis kits, represented a possible source of sensitization [7].
  • A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis [8].
  • Anion-blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors [9].
  • INTERPRETATION: A single fibrinogen/LDL apheresis lasting for 2 h could be used as an alternative to conventional infusion treatment and prednisolone for 10 days [10].

Chemical compound and disease context of Blood Component Removal


Biological context of Blood Component Removal


Anatomical context of Blood Component Removal


Associations of Blood Component Removal with chemical compounds

  • Changes in serum lipoproteins were similar in both groups apart from greater lowering by apheresis of LDL cholesterol (3.2 vs 3.4 mmol/L in drug group, p = 0.03) and lipoprotein(a) (geometric means 14 vs 21 mg/dL, p = 0.03) [1].
  • Low-density-lipoprotein (LDL) apheresis has the theoretical advantage over anion-exchange resins and hydroxymethylglutaryl coenzyme A inhibitors of decreasing lipoprotein(a) as well as LDL [1].
  • Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis [26].
  • Mean intima-media thickness decreased by a mean +/- SD of 0.05 +/- 0.34 mm in the apheresis group and increased by 0.06 +/- 0.38 mm in the simvastatin-only group (P < 0.001) [2].
  • In two patients subjected to plasmapheresis and volume replacement with albumin and isotonic saline, plasma EPI levels returned to one-half of the levels before pheresis within about one day [27].

Gene context of Blood Component Removal

  • We report here the obtaining of a virtually pure population of DCs (89.7% +/- 6%, n = 18) after culturing adherent apheresis cells for 7 days with granulocyte-macrophage colony-stimulating factor (GM-CSF ) and interleukin-4 (IL-4) [28].
  • Generation of interleukin 8 in stored apheresis platelet concentrates and the preventive effect of prestorage ultraviolet B radiation [29].
  • Finally, soluble VCAM was equally significantly elevated on the days of apheresis [30].
  • Following overnight ex vivo IL-2 activation of the pheresis product, the cells were reinfused the following day [31].
  • We also studied the plasma levels of SDF-1 in apheresis collection of these patients [32].

Analytical, diagnostic and therapeutic context of Blood Component Removal


  1. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Thompson, G.R., Maher, V.M., Matthews, S., Kitano, Y., Neuwirth, C., Shortt, M.B., Davies, G., Rees, A., Mir, A., Prescott, R.J. Lancet (1995) [Pubmed]
  2. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Kroon, A.A., van Asten, W.N., Stalenhoef, A.F. Ann. Intern. Med. (1996) [Pubmed]
  3. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Somlo, G., Sniecinski, I., ter Veer, A., Longmate, J., Knutson, G., Vuk-Pavlovic, S., Bhatia, R., Chow, W., Leong, L., Morgan, R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., Forman, S., Jones, D., Ashby, M., Fyfe, G., Hellmann, S., Doroshow, J.H. Blood (1999) [Pubmed]
  4. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Facon, T., Harousseau, J.L., Maloisel, F., Attal, M., Odriozola, J., Alegre, A., Schroyens, W., Hulin, C., Schots, R., Marin, P., Guilhot, F., Granena, A., De Waele, M., Pigneux, A., Méresse, V., Clark, P., Reiffers, J. Blood (1999) [Pubmed]
  5. Immunohistochemical distribution of lipoprotein epitopes in xanthomata from patients with familial hypercholesterolemia. Sugiyama, N., Marcovina, S., Gown, A.M., Seftel, H., Joffe, B., Chait, A. Am. J. Pathol. (1992) [Pubmed]
  6. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. Miller, F.W., Leitman, S.F., Cronin, M.E., Hicks, J.E., Leff, R.L., Wesley, R., Fraser, D.D., Dalakas, M., Plotz, P.H. N. Engl. J. Med. (1992) [Pubmed]
  7. Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. Leitman, S.F., Boltansky, H., Alter, H.J., Pearson, F.C., Kaliner, M.A. N. Engl. J. Med. (1986) [Pubmed]
  8. A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. Wallace, D., Goldfinger, D., Lowe, C., Nichols, S., Weiner, J., Brachman, M., Klinenberg, J.R. N. Engl. J. Med. (1982) [Pubmed]
  9. Anion-blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors. Agishi, T. JAMA (1994) [Pubmed]
  10. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Suckfüll, M. Lancet (2002) [Pubmed]
  11. Homozygous familial hypercholesterolemia. Selective removal of low-density lipoproteins by secondary membrane filtration. Leitman, S.F., Smith, J.W., Gregg, R.E. Transfusion (1989) [Pubmed]
  12. Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Popov, D., Zarrabi, M.H., Foda, H., Graber, M. Am. J. Kidney Dis. (1997) [Pubmed]
  13. QTc prolongation in apheresis platelet donors. Laspina, S.J., Browne, M.A., McSweeney, E.N., Lawlor, J., Whelan, D.M., Kinsella, A.L., Murphy, W.G. Transfusion (2002) [Pubmed]
  14. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Gómez-Espuch, J., Moraleda, J.M., Ortuño, F., Lozano, M.L., Ayala, F., Vallejo, C., de Arriba, F., Vicente, V. Bone Marrow Transplant. (2000) [Pubmed]
  15. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Geiss, H.C., Parhofer, K.G., Schwandt, P. J. Intern. Med. (1999) [Pubmed]
  16. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Sampietro, T., Tuoni, M., Ferdeghini, M., Ciardi, A., Marraccini, P., Prontera, C., Sassi, G., Taddei, M., Bionda, A. Circulation (1997) [Pubmed]
  17. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Tamai, O., Matsuoka, H., Itabe, H., Wada, Y., Kohno, K., Imaizumi, T. Circulation (1997) [Pubmed]
  18. Determinants of ABH expression on human blood platelets. Cooling, L.L., Kelly, K., Barton, J., Hwang, D., Koerner, T.A., Olson, J.D. Blood (2005) [Pubmed]
  19. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Wengler, G., Gorlin, J.B., Williamson, J.M., Rosen, F.S., Bing, D.H. Blood (1995) [Pubmed]
  20. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. Demirer, T., Rowley, S., Buckner, C.D., Appelbaum, F.R., Lilleby, K., Storb, R., Schiffman, K., Bensinger, W.I. J. Clin. Oncol. (1995) [Pubmed]
  21. Peripheral blood harvest of unaffected CD34+ CD38- hematopoietic precursors in paroxysmal nocturnal hemoglobinuria. Prince, G.M., Nguyen, M., Lazarus, H.M., Brodsky, R.A., Terstappen, L.W., Medof, M.E. Blood (1995) [Pubmed]
  22. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Kajinami, K., Mabuchi, H. Curr. Opin. Lipidol. (1999) [Pubmed]
  23. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Cowan, K.H., Moscow, J.A., Huang, H., Zujewski, J.A., O'Shaughnessy, J., Sorrentino, B., Hines, K., Carter, C., Schneider, E., Cusack, G., Noone, M., Dunbar, C., Steinberg, S., Wilson, W., Goldspiel, B., Read, E.J., Leitman, S.F., McDonagh, K., Chow, C., Abati, A., Chiang, Y., Chang, Y.N., Gottesman, M.M., Pastan, I., Nienhuis, A. Clin. Cancer Res. (1999) [Pubmed]
  24. Collection of two consecutive neutrophil concentrates for transfusion from donors mobilized with glycosylated granulocyte-CSF plus dexamethasone. Heuft, H.G., Goudeva, L., Schwella, N., Blasczyk, R. Transfusion (2004) [Pubmed]
  25. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial. Sanmartí, R., Marsal, S., Valverde, J., Casado, E., Lafuente, R., Kashiwagi, N., Rodriguez-Cros, J.R., Erra, A., Reina, D., Gratacós, J. Rheumatology (Oxford, England) (2005) [Pubmed]
  26. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis. Davidson, D.C., Peart, I., Turner, S., Sangster, M. Lancet (1994) [Pubmed]
  27. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. Warr, T.A., Warn-Cramer, B.J., Rao, L.V., Rapaport, S.I. Blood (1989) [Pubmed]
  28. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Tarte, K., Lu, Z.Y., Fiol, G., Legouffe, E., Rossi, J.F., Klein, B. Blood (1997) [Pubmed]
  29. Generation of interleukin 8 in stored apheresis platelet concentrates and the preventive effect of prestorage ultraviolet B radiation. Fujihara, M., Takahashi, T.A., Ogiso, C., Hosoda, M., Ikebuchi, K., Sekiguchi, S. Transfusion (1997) [Pubmed]
  30. Matrix metalloproteinase-9 (gelatinase B) is elevated during mobilization of peripheral blood progenitor cells by G-CSF. Carstanjen, D., Ulbricht, N., Iacone, A., Regenfus, M., Salama, A. Transfusion (2002) [Pubmed]
  31. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Burns, L.J., Weisdorf, D.J., DeFor, T.E., Vesole, D.H., Repka, T.L., Blazar, B.R., Burger, S.R., Panoskaltsis-Mortari, A., Keever-Taylor, C.A., Zhang, M.J., Miller, J.S. Bone Marrow Transplant. (2003) [Pubmed]
  32. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Gazitt, Y., Akay, C. Stem Cells (2004) [Pubmed]
  33. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Gazitt, Y., Tian, E., Barlogie, B., Reading, C.L., Vesole, D.H., Jagannath, S., Schnell, J., Hoffman, R., Tricot, G. Blood (1996) [Pubmed]
  34. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Hidaka, T., Suzuki, K., Matsuki, Y., Takamizawa-Matsumoto, M., Kataharada, K., Ishizuka, T., Kawakami, M., Nakamura, H. Arthritis Rheum. (1999) [Pubmed]
  35. The clinical features and treatment of arteriosclerosis obliterans with diabetes. Tsushima, N., Matsuo, H., Hayashi, T., Homma, S. Diabetes (1996) [Pubmed]
  36. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Aengevaeren, W.R., Kroon, A.A., Stalenhoef, A.F., Uijen, G.J., van der Werf, T. J. Am. Coll. Cardiol. (1996) [Pubmed]
  37. Influence of plasma exchange pheresis on plasma elimination of ceftriaxone. Bakken, J.S., Cavalieri, S.J., Gangeness, D. Antimicrob. Agents Chemother. (1990) [Pubmed]
WikiGenes - Universities